Dr. Martens (DRMT.Y) 주식 개요닥터마틴은 닥터마틴 브랜드로 신발을 디자인, 개발, 조달, 마케팅, 판매 및 유통하는 기업입니다. 자세히 보기DRMT.Y 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장3/6과거 실적3/6재무 건전성6/6배당2/6강점공정 가치 추정치보다 낮은 20% 에서 거래수익은 매년 30.06% 증가할 것으로 예상됩니다.지난 1년간 수익이 413.1% 증가했습니다.위험 분석주식은 유동성이 매우 낮습니다3.52% 의 배당금은 수익으로 잘 충당되지 않습니다.재무 결과에 영향을 미치는 대규모 일회성 항목모든 위험 점검 보기DRMT.Y Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW502,832 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG502,832 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$1.91151.7% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-11m1b2016201920222025202620282031Revenue UK£954.9mEarnings UK£29.7mAdvancedSet Fair ValueView all narrativesDr. Martens plc 경쟁사Wolverine World WideSymbol: NYSE:WWWMarket cap: US$1.4bRocky BrandsSymbol: NasdaqGS:RCKYMarket cap: US$300.8mSteven MaddenSymbol: NasdaqGS:SHOOMarket cap: US$2.9bMcRae IndustriesSymbol: OTCPK:MCRA.AMarket cap: US$106.3m가격 이력 및 성과Dr. Martens 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가UK£1.9152주 최고가UK£2.6052주 최저가UK£1.43베타0.241개월 변동4.52%3개월 변동12.12%1년 변동n/a3년 변동-44.23%5년 변동n/aIPO 이후 변동-81.77%최근 뉴스 및 업데이트공시 • Jul 01Dr. Martens plc Announces Board and Committees Appointments, Effective July 15, 2026Dr. Martens plc announced the appointment of Melanie Richards CBE as an Independent Non-Executive Director of the Company, with effect from the conclusion of the Company's Annual General Meeting on July 15, 2026. Melanie Richards is former Deputy Chair of KPMG UK and currently serves as Chair of Azets and as a Non-Executive Director of Morgan Stanley & Co. International and HKA Global. She brings broad-based executive, commercial, financial and capital markets experience, together with significant board and advisory experience and a strong track record of contributing to strategic direction and commercial performance in complex organisations. Upon joining the Board, Melanie Richards will be appointed Senior Independent Director and Chair of the Nomination Committee, and will also become a member of the Audit and Risk Committee and the Remuneration Committee. Andrew Harrison, Independent Non-Executive Director, will be appointed Chair of the Remuneration Committee. These appointments will take effect from the conclusion of the 2026 AGM. Lynne Weedall will step down from the Board following the 2026 AGM.공시 • May 30Dr. Martens plc Announces Stepping Down of Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, Effective July 15, 2026Dr. Martens PLC announced that Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, had informed the Board of her intention to step down at the conclusion of the 2026 Annual General Meeting on July 15, 2026 after almost six years on the Board. Lynne Weedall will therefore not seek re-election at the 2026 AGM. A thorough succession process to appoint Lynne Weedall's replacement on the Board is well progressed and a further announcement will be made in due course.공시 • May 28Dr. Martens plc, Annual General Meeting, Jul 15, 2026Dr. Martens plc, Annual General Meeting, Jul 15, 2026.공시 • May 06Dr. Martens plc to Report Fiscal Year 2026 Results on May 19, 2026Dr. Martens plc announced that they will report fiscal year 2026 results at 6:00 AM, Coordinated Universal Time on May 19, 2026공시 • Nov 21Dr. Martens plc Declares Interim Dividend, Payable on April 9, 2026The Board of Dr. Martens plc declared an interim dividend of 0.85 pence per share (Sep 24: 0.85 pence). This will be paid on 9 April 2026 to shareholders on the register as at 6 March 2026.공시 • Nov 13Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare CollectionGen Phoenixand heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands' shared commitment to long-term impact over one-off pilots and capsules. According to one report, more than 380 brand-innovator collaborations launched in 2023, though many exist as exploratory, pilot or capsule partnerships in nature rather than multi-year programs. Against that backdrop, Gen Phoenix and Dr. Martens stand out as a rare example of a long-term strategic partnership. From its first collection of Genix Nappa reclaimed leather boots in 2024 to the Solar Flare line - which for the very first time includes kids' footwear and bags - the brands have steadily expanded the use of Gen Phoenix's material made from recycled leather fibres across categories while maintaining Dr. Martens' signature durability and comfort. Each season has pushed the boundaries of what heritage design can look like when paired with next-generation materials, furthering a trend Gen Phoenix has pioneered called "luxcycling" turning waste into premium recycled materials without compromising style or quality. Introducing the Next Generation: Solar Flare Kids' Boot: With the launch of the Solar Flare kids' boot, Dr. Martens brings its reclaimed leather innovation to a new audience. The Solar Flare kids boot is crafted from Gen Phoenix's soft and lightweight yet durable Genix Nappa material, with a silver sun, moon and star print across the upper, delivering the same comfort of the original adult Genix Nappa styles. Perfect for growing feet that don't keep still, while aligning with the values of climate conscious shoppers and wearers. Expanding the Circular Revolution: From Boots to Bags: The Solar Flare collection also introduces Dr. Martens' first bag crafted from Gen Phoenix's reclaimed leather material, a category expansion that demonstrates the scalability of Gen Phoenix's circular technology platform. Together, the brands continue to advance their shared goal of achieving net-zero emissions by 2040, showing how material innovation can be woven into iconic design without compromising identity or integrity. To date, Gen Phoenix has helped Dr. Martens: Divert 15 tonnes of leather offcuts from going to waste, roughly the weight of 15 compact cars; Save 693 tCO2e compared to conventional leather, approximately 1.7 million air miles, or 300 round-trip flights from London to New York. These joint efforts from Gen Phoenix and Dr. Martened to transform landfill-destined leather into high-performance Genix Nappa material have resulted in four seasons of durable, comfortable, waste-reducing footwear and accessories. The partnership embodies a simple philosophy: reclaimed leather, remade to last.더 많은 업데이트 보기Recent updates공시 • Jul 01Dr. Martens plc Announces Board and Committees Appointments, Effective July 15, 2026Dr. Martens plc announced the appointment of Melanie Richards CBE as an Independent Non-Executive Director of the Company, with effect from the conclusion of the Company's Annual General Meeting on July 15, 2026. Melanie Richards is former Deputy Chair of KPMG UK and currently serves as Chair of Azets and as a Non-Executive Director of Morgan Stanley & Co. International and HKA Global. She brings broad-based executive, commercial, financial and capital markets experience, together with significant board and advisory experience and a strong track record of contributing to strategic direction and commercial performance in complex organisations. Upon joining the Board, Melanie Richards will be appointed Senior Independent Director and Chair of the Nomination Committee, and will also become a member of the Audit and Risk Committee and the Remuneration Committee. Andrew Harrison, Independent Non-Executive Director, will be appointed Chair of the Remuneration Committee. These appointments will take effect from the conclusion of the 2026 AGM. Lynne Weedall will step down from the Board following the 2026 AGM.공시 • May 30Dr. Martens plc Announces Stepping Down of Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, Effective July 15, 2026Dr. Martens PLC announced that Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, had informed the Board of her intention to step down at the conclusion of the 2026 Annual General Meeting on July 15, 2026 after almost six years on the Board. Lynne Weedall will therefore not seek re-election at the 2026 AGM. A thorough succession process to appoint Lynne Weedall's replacement on the Board is well progressed and a further announcement will be made in due course.공시 • May 28Dr. Martens plc, Annual General Meeting, Jul 15, 2026Dr. Martens plc, Annual General Meeting, Jul 15, 2026.공시 • May 06Dr. Martens plc to Report Fiscal Year 2026 Results on May 19, 2026Dr. Martens plc announced that they will report fiscal year 2026 results at 6:00 AM, Coordinated Universal Time on May 19, 2026공시 • Nov 21Dr. Martens plc Declares Interim Dividend, Payable on April 9, 2026The Board of Dr. Martens plc declared an interim dividend of 0.85 pence per share (Sep 24: 0.85 pence). This will be paid on 9 April 2026 to shareholders on the register as at 6 March 2026.공시 • Nov 13Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare CollectionGen Phoenixand heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands' shared commitment to long-term impact over one-off pilots and capsules. According to one report, more than 380 brand-innovator collaborations launched in 2023, though many exist as exploratory, pilot or capsule partnerships in nature rather than multi-year programs. Against that backdrop, Gen Phoenix and Dr. Martens stand out as a rare example of a long-term strategic partnership. From its first collection of Genix Nappa reclaimed leather boots in 2024 to the Solar Flare line - which for the very first time includes kids' footwear and bags - the brands have steadily expanded the use of Gen Phoenix's material made from recycled leather fibres across categories while maintaining Dr. Martens' signature durability and comfort. Each season has pushed the boundaries of what heritage design can look like when paired with next-generation materials, furthering a trend Gen Phoenix has pioneered called "luxcycling" turning waste into premium recycled materials without compromising style or quality. Introducing the Next Generation: Solar Flare Kids' Boot: With the launch of the Solar Flare kids' boot, Dr. Martens brings its reclaimed leather innovation to a new audience. The Solar Flare kids boot is crafted from Gen Phoenix's soft and lightweight yet durable Genix Nappa material, with a silver sun, moon and star print across the upper, delivering the same comfort of the original adult Genix Nappa styles. Perfect for growing feet that don't keep still, while aligning with the values of climate conscious shoppers and wearers. Expanding the Circular Revolution: From Boots to Bags: The Solar Flare collection also introduces Dr. Martens' first bag crafted from Gen Phoenix's reclaimed leather material, a category expansion that demonstrates the scalability of Gen Phoenix's circular technology platform. Together, the brands continue to advance their shared goal of achieving net-zero emissions by 2040, showing how material innovation can be woven into iconic design without compromising identity or integrity. To date, Gen Phoenix has helped Dr. Martens: Divert 15 tonnes of leather offcuts from going to waste, roughly the weight of 15 compact cars; Save 693 tCO2e compared to conventional leather, approximately 1.7 million air miles, or 300 round-trip flights from London to New York. These joint efforts from Gen Phoenix and Dr. Martened to transform landfill-destined leather into high-performance Genix Nappa material have resulted in four seasons of durable, comfortable, waste-reducing footwear and accessories. The partnership embodies a simple philosophy: reclaimed leather, remade to last.공시 • Jun 18Dr. Martens plc to Report First Half, 2026 Results on Nov 20, 2025Dr. Martens plc announced that they will report first half, 2026 results on Nov 20, 2025공시 • Jun 17Dr. Martens plc, Annual General Meeting, Jul 10, 2025Dr. Martens plc, Annual General Meeting, Jul 10, 2025. Location: 1 11 hawley crescent, camden, nw1 8np, london United Kingdom공시 • Jun 05Dr. Martens plc Proposes Final Dividend for Fiscal Year 2025, Payable on 8 October 2025The Board of Dr. Martens plc proposed a final dividend of 1.70 pence, taking the total dividend for fiscal year 2025, including the interim dividend of 0.85 pence, to 2.55 pence (fiscal year 2024: 2.55 pence). This will be paid to shareholders on the register as at 29 August 2025 with payment on 8 October 2025. The proposed dividend is subject to shareholder approval.공시 • Feb 12Dr. Martens plc Announces the Appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors with Effect from 26 March 2025Dr. Martens plc announced the appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors of the Company with effect from 26 March 2025. Robert is an experienced executive with a strong track record of delivering growth at consumer brands. He was CEO of John Hardy and American Eagle Outfitters and also served as EVP Wines and Spirits for Constellation Brands. Prior to this he served for over a decade in senior roles at Levi Strauss & Co, including as President of the Americas division and, latterly, as Global Brand President, Americas. Robert brings a broad, multidisciplinary skillset and significant experience of the North American market combined with global expertise. His prior non-executive experience includes positions on the boards of Canopy Growth, Urban Outfitters and Constellation Brands. He was recently appointed as CEO of US wine company The Duckhorn Portfolio. Benoit is a Partner at the Company's largest investor, global investment firm Permira, where he is a member of the Investment and Executive Committees. He has served on the board of Spanish online travel company eDreams ODIGEO as a Non-Executive Director for a decade, during which time the business has undergone a significant period of transformation. Benoit also serves on the board of Permira Holdings Limited and has previously served on the boards of Universidad Europea, VacanceSelect and Exclusive Networks. He has worked at Permira since 2006, and previously spent six years at JPMorgan in London and Frankfurt.공시 • Dec 03Dr. Martens plc to Report Fiscal Year 2025 Results on Jun 05, 2025Dr. Martens plc announced that they will report fiscal year 2025 results on Jun 05, 2025공시 • Nov 28+ 1 more updateDr. Martens plc Announces Chief Executive Officer ChangesDr. Martens plc announced further to the company's previous announcement on 16 April 2024 that Ije Nwokorie would succeed Kenny Wilson as its new Chief Executive Officer before the end of the fiscal year 2025, Dr. Martens announced that Ije's appointment will take effect from 6 January 2025. The Company also confirms that Kenny Wilson will step down from the Board on 6 January 2025. Kenny will remain available to Ije and the wider Global Leadership Team until 31 March 2025 to ensure a smooth handover.공시 • Oct 08Dr. Martens plc to Report First Half, 2025 Results on Nov 28, 2024Dr. Martens plc announced that they will report first half, 2025 results on Nov 28, 2024공시 • Jun 14Dr. Martens plc, Annual General Meeting, Jul 11, 2024Dr. Martens plc, Annual General Meeting, Jul 11, 2024. Location: holiday inn london camden lock, 30 jamestown road, camden, nw1 7by, london United Kingdom공시 • Jun 05Dr. Martens plc Announces Executive ChangesDr. Martens plc announced that Katherine Bellau has been appointed as Company Secretary with effect from 3 June 2024. Katherine succeeds Emily Reichwald, who will be taking up a different role within the business.공시 • Jun 02Dr. Martens plc Proposes Final Dividend for Fiscal Year Ended 31 March 2024, Payable on 1 October 2024The board of Dr. Martens plc has proposed, subject to shareholder approval, a final dividend of 0.99 pence (fiscal year 2023: 4.28 pence), taking the total dividend for fiscal year ended 31 March 2024, including the interim dividend of 1.56 pence, to 2.55 pence, a 35% payout ratio. Whilst this is a year-on-year reduction given the higher payout in fiscal year 2023 and lower earnings achieved 2024, the 35% payout for fiscal year 2024 is at the top of the policy range. The board's intention is to hold the fiscal year 2025 dividend flat in absolute terms, before returning to an earnings payout in line with its dividend policy (of 25% to 35% payout) in fiscal year 2026 onwards. The final dividend for fiscal year 2024 will be paid to shareholders on the register as at 30 August 2024 with payment on 1 October 2024.공시 • May 21Marathon Partners Urges Dr. Martens to Buy Back StockOn May 20, 2024, Marathon Partners Equity Management announced that it is turning up the heat on Dr. Martens plc by urging the Company to detail planned expense cuts and to buy back stock.공시 • Apr 17Dr. Martens plc Announces CEO ChangesDr. Martens plc announced that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board announced that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season. Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of water UK.공시 • Apr 03Marathon Partners Calls for Strategic Review Process for Dr. MartensOn April 2, 2024, Marathon Partners Equity Management, LLC and its affiliated investment funds announced that they recently delivered a letter to Chairman Paul Mason and the Board of Directors, urging the Board to commence a process of evaluating alternatives to maximize shareholder value, including a potential sale of Dr. Martens plc. In the letter to the Board, Marathon Partners recommended that the Company’s Board hire an advisor and commence a strategic review process, including a potential sale or merger of the Company to interested parties, with the express goal of maximizing shareholder value. Marathon Partners stated that prior to the release of its letter, it held discussions with multiple Directors of the Company to privately resolve these matters. Marathon Partners also stated that while these conversations were friendly and productive, they did not lead to a satisfactory resolution of important shareholder issues.공시 • Feb 27Giles Wilson to Join Dr. Martens plc as CFO on May 27, 2024Dr. Martens plc announced that Giles Wilson, who has been appointed to the role of Chief Financial Officer (CFO), will join the business and Board on 27th May 2024 and will present the fiscal year 2024 results on 30th May 2024.공시 • Nov 30Dr. Martens plc Approves Interim Dividend, Payable on 2 February 2024Dr. Martens plc has approved and the Company has declared an interim dividend of 1.56p per share (2023: 1.56 pence). The interim dividend will be paid to shareholders on the register as at 5 January 2024 with payment on 2 February 2024.공시 • Nov 17+ 1 more updateDr. Martens plc Announces Management ChangesDr. Martens plc announced that Non-Executive Director Ije Nwokorie will join as Chief Brand Officer from 1st February 2024. On appointment into this role, Ije will cease to be a member of the Board and will step down as a member of the Audit and Risk, Nomination and Disclosure committees. The newly-created role of Chief Brand Officer will be a key member of the global leadership team, reporting into Kenny Wilson, CEO, overseeing the Global Marketing, Product and Strategy functions. The Chief Brand Officer will be responsible for setting the overall brand strategy, vision and direction for the next phase of Dr. Martens' growth. Ije will join Dr. Martens as Chief Brand Officer from Apple Inc, where he has been Senior Director, Apple Retail since January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.공시 • Nov 14Dr. Martens plc to Report Fiscal Year 2024 Results on May 30, 2024Dr. Martens plc announced that they will report fiscal year 2024 results on May 30, 2024공시 • Jun 01+ 2 more updatesDr. Martens plc to Report First Half, 2024 Results on Nov 30, 2023Dr. Martens plc announced that they will report first half, 2024 results on Nov 30, 2023공시 • Jan 19Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023Dr. Martens plc provided revenue guidance for fiscal year 2023. For the period, revenue growth for the revenue on an actual currency basis will now be 11%-13% (4-6% CC).공시 • Jul 14Dr. Martens plc to Report Fiscal Year 2023 Results on Jun 01, 2023Dr. Martens plc announced that they will report fiscal year 2023 results on Jun 01, 2023주주 수익률DRMT.YUS LuxuryUS 시장7D6.3%2.4%-0.7%1Yn/a-14.6%20.3%전체 주주 수익률 보기수익률 대 산업: DRMT.Y의 US Luxury 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: DRMT.Y의 US 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is DRMT.Y's price volatile compared to industry and market?DRMT.Y volatilityDRMT.Y Average Weekly Movementn/aLuxury Industry Average Movement6.9%Market Average Movement7.3%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.2%안정적인 주가: DRMT.Y의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine DRMT.Y의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트19452,377Ije Nwokoriewww.drmartensplc.com닥터마틴은 유럽, 중동, 아프리카, 미주 및 아시아 태평양 지역에서 닥터마틴 브랜드로 신발을 디자인, 개발, 조달, 마케팅, 판매 및 유통하는 회사입니다. 이 회사는 1945년에 설립되었으며 영국 런던에 본사를 두고 있습니다.더 보기Dr. Martens plc 기초 지표 요약Dr. Martens의 순이익과 매출은 시가총액과 어떻게 비교됩니까?DRMT.Y 기초 통계시가총액US$925.87m순이익 (TTM)US$31.80m매출 (TTM)US$1.02b29.1x주가수익비율(P/E)0.9x주가매출비율(P/S)DRMT.Y는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표DRMT.Y 손익계산서 (TTM)매출UK£764.90m매출원가UK£258.90m총이익UK£506.00m기타 비용UK£482.20m순이익UK£23.80m최근 보고된 실적Mar 29, 2026다음 실적 발표일해당 없음주당순이익(EPS)0.025총이익률66.15%순이익률3.11%부채/자본 비율69.1%DRMT.Y의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당3.5%현재 배당 수익률103%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/08 18:09종가2026/07/06 00:00수익2026/03/29연간 수익2026/03/29데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Dr. Martens plc는 13명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Richard TaylorBarclaysAnne CritchlowBerenbergDavid RouxBofA Global Research10명의 분석가 더 보기
공시 • Jul 01Dr. Martens plc Announces Board and Committees Appointments, Effective July 15, 2026Dr. Martens plc announced the appointment of Melanie Richards CBE as an Independent Non-Executive Director of the Company, with effect from the conclusion of the Company's Annual General Meeting on July 15, 2026. Melanie Richards is former Deputy Chair of KPMG UK and currently serves as Chair of Azets and as a Non-Executive Director of Morgan Stanley & Co. International and HKA Global. She brings broad-based executive, commercial, financial and capital markets experience, together with significant board and advisory experience and a strong track record of contributing to strategic direction and commercial performance in complex organisations. Upon joining the Board, Melanie Richards will be appointed Senior Independent Director and Chair of the Nomination Committee, and will also become a member of the Audit and Risk Committee and the Remuneration Committee. Andrew Harrison, Independent Non-Executive Director, will be appointed Chair of the Remuneration Committee. These appointments will take effect from the conclusion of the 2026 AGM. Lynne Weedall will step down from the Board following the 2026 AGM.
공시 • May 30Dr. Martens plc Announces Stepping Down of Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, Effective July 15, 2026Dr. Martens PLC announced that Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, had informed the Board of her intention to step down at the conclusion of the 2026 Annual General Meeting on July 15, 2026 after almost six years on the Board. Lynne Weedall will therefore not seek re-election at the 2026 AGM. A thorough succession process to appoint Lynne Weedall's replacement on the Board is well progressed and a further announcement will be made in due course.
공시 • May 28Dr. Martens plc, Annual General Meeting, Jul 15, 2026Dr. Martens plc, Annual General Meeting, Jul 15, 2026.
공시 • May 06Dr. Martens plc to Report Fiscal Year 2026 Results on May 19, 2026Dr. Martens plc announced that they will report fiscal year 2026 results at 6:00 AM, Coordinated Universal Time on May 19, 2026
공시 • Nov 21Dr. Martens plc Declares Interim Dividend, Payable on April 9, 2026The Board of Dr. Martens plc declared an interim dividend of 0.85 pence per share (Sep 24: 0.85 pence). This will be paid on 9 April 2026 to shareholders on the register as at 6 March 2026.
공시 • Nov 13Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare CollectionGen Phoenixand heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands' shared commitment to long-term impact over one-off pilots and capsules. According to one report, more than 380 brand-innovator collaborations launched in 2023, though many exist as exploratory, pilot or capsule partnerships in nature rather than multi-year programs. Against that backdrop, Gen Phoenix and Dr. Martens stand out as a rare example of a long-term strategic partnership. From its first collection of Genix Nappa reclaimed leather boots in 2024 to the Solar Flare line - which for the very first time includes kids' footwear and bags - the brands have steadily expanded the use of Gen Phoenix's material made from recycled leather fibres across categories while maintaining Dr. Martens' signature durability and comfort. Each season has pushed the boundaries of what heritage design can look like when paired with next-generation materials, furthering a trend Gen Phoenix has pioneered called "luxcycling" turning waste into premium recycled materials without compromising style or quality. Introducing the Next Generation: Solar Flare Kids' Boot: With the launch of the Solar Flare kids' boot, Dr. Martens brings its reclaimed leather innovation to a new audience. The Solar Flare kids boot is crafted from Gen Phoenix's soft and lightweight yet durable Genix Nappa material, with a silver sun, moon and star print across the upper, delivering the same comfort of the original adult Genix Nappa styles. Perfect for growing feet that don't keep still, while aligning with the values of climate conscious shoppers and wearers. Expanding the Circular Revolution: From Boots to Bags: The Solar Flare collection also introduces Dr. Martens' first bag crafted from Gen Phoenix's reclaimed leather material, a category expansion that demonstrates the scalability of Gen Phoenix's circular technology platform. Together, the brands continue to advance their shared goal of achieving net-zero emissions by 2040, showing how material innovation can be woven into iconic design without compromising identity or integrity. To date, Gen Phoenix has helped Dr. Martens: Divert 15 tonnes of leather offcuts from going to waste, roughly the weight of 15 compact cars; Save 693 tCO2e compared to conventional leather, approximately 1.7 million air miles, or 300 round-trip flights from London to New York. These joint efforts from Gen Phoenix and Dr. Martened to transform landfill-destined leather into high-performance Genix Nappa material have resulted in four seasons of durable, comfortable, waste-reducing footwear and accessories. The partnership embodies a simple philosophy: reclaimed leather, remade to last.
공시 • Jul 01Dr. Martens plc Announces Board and Committees Appointments, Effective July 15, 2026Dr. Martens plc announced the appointment of Melanie Richards CBE as an Independent Non-Executive Director of the Company, with effect from the conclusion of the Company's Annual General Meeting on July 15, 2026. Melanie Richards is former Deputy Chair of KPMG UK and currently serves as Chair of Azets and as a Non-Executive Director of Morgan Stanley & Co. International and HKA Global. She brings broad-based executive, commercial, financial and capital markets experience, together with significant board and advisory experience and a strong track record of contributing to strategic direction and commercial performance in complex organisations. Upon joining the Board, Melanie Richards will be appointed Senior Independent Director and Chair of the Nomination Committee, and will also become a member of the Audit and Risk Committee and the Remuneration Committee. Andrew Harrison, Independent Non-Executive Director, will be appointed Chair of the Remuneration Committee. These appointments will take effect from the conclusion of the 2026 AGM. Lynne Weedall will step down from the Board following the 2026 AGM.
공시 • May 30Dr. Martens plc Announces Stepping Down of Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, Effective July 15, 2026Dr. Martens PLC announced that Lynne Weedall, Senior Independent Director and Chair of the Remuneration and Nomination Committees, had informed the Board of her intention to step down at the conclusion of the 2026 Annual General Meeting on July 15, 2026 after almost six years on the Board. Lynne Weedall will therefore not seek re-election at the 2026 AGM. A thorough succession process to appoint Lynne Weedall's replacement on the Board is well progressed and a further announcement will be made in due course.
공시 • May 28Dr. Martens plc, Annual General Meeting, Jul 15, 2026Dr. Martens plc, Annual General Meeting, Jul 15, 2026.
공시 • May 06Dr. Martens plc to Report Fiscal Year 2026 Results on May 19, 2026Dr. Martens plc announced that they will report fiscal year 2026 results at 6:00 AM, Coordinated Universal Time on May 19, 2026
공시 • Nov 21Dr. Martens plc Declares Interim Dividend, Payable on April 9, 2026The Board of Dr. Martens plc declared an interim dividend of 0.85 pence per share (Sep 24: 0.85 pence). This will be paid on 9 April 2026 to shareholders on the register as at 6 March 2026.
공시 • Nov 13Gen Phoenix and Dr. Martens Celebrate Four Seasons of Waste Reduction with the Launch of the Solar Flare CollectionGen Phoenixand heritage footwear brand Dr. Martens are marking a major milestone in sustainable design: four consecutive seasons of partnership. In celebration of this continued collaboration, which began with the launch of the Genix Nappa collection in 2024, and just in time for the holidays, Dr. Martens is introducing the Solar Flare collection made with Genix Nappa to underscore both brands' shared commitment to long-term impact over one-off pilots and capsules. According to one report, more than 380 brand-innovator collaborations launched in 2023, though many exist as exploratory, pilot or capsule partnerships in nature rather than multi-year programs. Against that backdrop, Gen Phoenix and Dr. Martens stand out as a rare example of a long-term strategic partnership. From its first collection of Genix Nappa reclaimed leather boots in 2024 to the Solar Flare line - which for the very first time includes kids' footwear and bags - the brands have steadily expanded the use of Gen Phoenix's material made from recycled leather fibres across categories while maintaining Dr. Martens' signature durability and comfort. Each season has pushed the boundaries of what heritage design can look like when paired with next-generation materials, furthering a trend Gen Phoenix has pioneered called "luxcycling" turning waste into premium recycled materials without compromising style or quality. Introducing the Next Generation: Solar Flare Kids' Boot: With the launch of the Solar Flare kids' boot, Dr. Martens brings its reclaimed leather innovation to a new audience. The Solar Flare kids boot is crafted from Gen Phoenix's soft and lightweight yet durable Genix Nappa material, with a silver sun, moon and star print across the upper, delivering the same comfort of the original adult Genix Nappa styles. Perfect for growing feet that don't keep still, while aligning with the values of climate conscious shoppers and wearers. Expanding the Circular Revolution: From Boots to Bags: The Solar Flare collection also introduces Dr. Martens' first bag crafted from Gen Phoenix's reclaimed leather material, a category expansion that demonstrates the scalability of Gen Phoenix's circular technology platform. Together, the brands continue to advance their shared goal of achieving net-zero emissions by 2040, showing how material innovation can be woven into iconic design without compromising identity or integrity. To date, Gen Phoenix has helped Dr. Martens: Divert 15 tonnes of leather offcuts from going to waste, roughly the weight of 15 compact cars; Save 693 tCO2e compared to conventional leather, approximately 1.7 million air miles, or 300 round-trip flights from London to New York. These joint efforts from Gen Phoenix and Dr. Martened to transform landfill-destined leather into high-performance Genix Nappa material have resulted in four seasons of durable, comfortable, waste-reducing footwear and accessories. The partnership embodies a simple philosophy: reclaimed leather, remade to last.
공시 • Jun 18Dr. Martens plc to Report First Half, 2026 Results on Nov 20, 2025Dr. Martens plc announced that they will report first half, 2026 results on Nov 20, 2025
공시 • Jun 17Dr. Martens plc, Annual General Meeting, Jul 10, 2025Dr. Martens plc, Annual General Meeting, Jul 10, 2025. Location: 1 11 hawley crescent, camden, nw1 8np, london United Kingdom
공시 • Jun 05Dr. Martens plc Proposes Final Dividend for Fiscal Year 2025, Payable on 8 October 2025The Board of Dr. Martens plc proposed a final dividend of 1.70 pence, taking the total dividend for fiscal year 2025, including the interim dividend of 0.85 pence, to 2.55 pence (fiscal year 2024: 2.55 pence). This will be paid to shareholders on the register as at 29 August 2025 with payment on 8 October 2025. The proposed dividend is subject to shareholder approval.
공시 • Feb 12Dr. Martens plc Announces the Appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors with Effect from 26 March 2025Dr. Martens plc announced the appointments of Robert Hanson and Benoit Vauchy as Non-Executive Directors of the Company with effect from 26 March 2025. Robert is an experienced executive with a strong track record of delivering growth at consumer brands. He was CEO of John Hardy and American Eagle Outfitters and also served as EVP Wines and Spirits for Constellation Brands. Prior to this he served for over a decade in senior roles at Levi Strauss & Co, including as President of the Americas division and, latterly, as Global Brand President, Americas. Robert brings a broad, multidisciplinary skillset and significant experience of the North American market combined with global expertise. His prior non-executive experience includes positions on the boards of Canopy Growth, Urban Outfitters and Constellation Brands. He was recently appointed as CEO of US wine company The Duckhorn Portfolio. Benoit is a Partner at the Company's largest investor, global investment firm Permira, where he is a member of the Investment and Executive Committees. He has served on the board of Spanish online travel company eDreams ODIGEO as a Non-Executive Director for a decade, during which time the business has undergone a significant period of transformation. Benoit also serves on the board of Permira Holdings Limited and has previously served on the boards of Universidad Europea, VacanceSelect and Exclusive Networks. He has worked at Permira since 2006, and previously spent six years at JPMorgan in London and Frankfurt.
공시 • Dec 03Dr. Martens plc to Report Fiscal Year 2025 Results on Jun 05, 2025Dr. Martens plc announced that they will report fiscal year 2025 results on Jun 05, 2025
공시 • Nov 28+ 1 more updateDr. Martens plc Announces Chief Executive Officer ChangesDr. Martens plc announced further to the company's previous announcement on 16 April 2024 that Ije Nwokorie would succeed Kenny Wilson as its new Chief Executive Officer before the end of the fiscal year 2025, Dr. Martens announced that Ije's appointment will take effect from 6 January 2025. The Company also confirms that Kenny Wilson will step down from the Board on 6 January 2025. Kenny will remain available to Ije and the wider Global Leadership Team until 31 March 2025 to ensure a smooth handover.
공시 • Oct 08Dr. Martens plc to Report First Half, 2025 Results on Nov 28, 2024Dr. Martens plc announced that they will report first half, 2025 results on Nov 28, 2024
공시 • Jun 14Dr. Martens plc, Annual General Meeting, Jul 11, 2024Dr. Martens plc, Annual General Meeting, Jul 11, 2024. Location: holiday inn london camden lock, 30 jamestown road, camden, nw1 7by, london United Kingdom
공시 • Jun 05Dr. Martens plc Announces Executive ChangesDr. Martens plc announced that Katherine Bellau has been appointed as Company Secretary with effect from 3 June 2024. Katherine succeeds Emily Reichwald, who will be taking up a different role within the business.
공시 • Jun 02Dr. Martens plc Proposes Final Dividend for Fiscal Year Ended 31 March 2024, Payable on 1 October 2024The board of Dr. Martens plc has proposed, subject to shareholder approval, a final dividend of 0.99 pence (fiscal year 2023: 4.28 pence), taking the total dividend for fiscal year ended 31 March 2024, including the interim dividend of 1.56 pence, to 2.55 pence, a 35% payout ratio. Whilst this is a year-on-year reduction given the higher payout in fiscal year 2023 and lower earnings achieved 2024, the 35% payout for fiscal year 2024 is at the top of the policy range. The board's intention is to hold the fiscal year 2025 dividend flat in absolute terms, before returning to an earnings payout in line with its dividend policy (of 25% to 35% payout) in fiscal year 2026 onwards. The final dividend for fiscal year 2024 will be paid to shareholders on the register as at 30 August 2024 with payment on 1 October 2024.
공시 • May 21Marathon Partners Urges Dr. Martens to Buy Back StockOn May 20, 2024, Marathon Partners Equity Management announced that it is turning up the heat on Dr. Martens plc by urging the Company to detail planned expense cuts and to buy back stock.
공시 • Apr 17Dr. Martens plc Announces CEO ChangesDr. Martens plc announced that Kenny Wilson has decided that this will be his final year as Chief Executive Officer (CEO) of the Company. As part of an orderly succession plan, and following a thorough search process, the Board announced that Ije Nwokorie, currently Chief Brand Officer (CBO), will succeed Kenny as CEO. Kenny and Ije will work together to ensure a smooth handover, with Ije becoming CEO before the end of the current financial year. Ije will remain as CBO in the meantime, with his focus being on the brand and driving demand ahead of the important AW24 season. Ije Nwokorie was a Non-Executive Director on the Board from January 2021 until early 2024, when he joined the business as Chief Brand Officer, with responsibility for product, marketing and strategy. Ije was previously at Apple Inc, where he was Senior Director, Apple Retail from January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of water UK.
공시 • Apr 03Marathon Partners Calls for Strategic Review Process for Dr. MartensOn April 2, 2024, Marathon Partners Equity Management, LLC and its affiliated investment funds announced that they recently delivered a letter to Chairman Paul Mason and the Board of Directors, urging the Board to commence a process of evaluating alternatives to maximize shareholder value, including a potential sale of Dr. Martens plc. In the letter to the Board, Marathon Partners recommended that the Company’s Board hire an advisor and commence a strategic review process, including a potential sale or merger of the Company to interested parties, with the express goal of maximizing shareholder value. Marathon Partners stated that prior to the release of its letter, it held discussions with multiple Directors of the Company to privately resolve these matters. Marathon Partners also stated that while these conversations were friendly and productive, they did not lead to a satisfactory resolution of important shareholder issues.
공시 • Feb 27Giles Wilson to Join Dr. Martens plc as CFO on May 27, 2024Dr. Martens plc announced that Giles Wilson, who has been appointed to the role of Chief Financial Officer (CFO), will join the business and Board on 27th May 2024 and will present the fiscal year 2024 results on 30th May 2024.
공시 • Nov 30Dr. Martens plc Approves Interim Dividend, Payable on 2 February 2024Dr. Martens plc has approved and the Company has declared an interim dividend of 1.56p per share (2023: 1.56 pence). The interim dividend will be paid to shareholders on the register as at 5 January 2024 with payment on 2 February 2024.
공시 • Nov 17+ 1 more updateDr. Martens plc Announces Management ChangesDr. Martens plc announced that Non-Executive Director Ije Nwokorie will join as Chief Brand Officer from 1st February 2024. On appointment into this role, Ije will cease to be a member of the Board and will step down as a member of the Audit and Risk, Nomination and Disclosure committees. The newly-created role of Chief Brand Officer will be a key member of the global leadership team, reporting into Kenny Wilson, CEO, overseeing the Global Marketing, Product and Strategy functions. The Chief Brand Officer will be responsible for setting the overall brand strategy, vision and direction for the next phase of Dr. Martens' growth. Ije will join Dr. Martens as Chief Brand Officer from Apple Inc, where he has been Senior Director, Apple Retail since January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.
공시 • Nov 14Dr. Martens plc to Report Fiscal Year 2024 Results on May 30, 2024Dr. Martens plc announced that they will report fiscal year 2024 results on May 30, 2024
공시 • Jun 01+ 2 more updatesDr. Martens plc to Report First Half, 2024 Results on Nov 30, 2023Dr. Martens plc announced that they will report first half, 2024 results on Nov 30, 2023
공시 • Jan 19Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023Dr. Martens plc provided revenue guidance for fiscal year 2023. For the period, revenue growth for the revenue on an actual currency basis will now be 11%-13% (4-6% CC).
공시 • Jul 14Dr. Martens plc to Report Fiscal Year 2023 Results on Jun 01, 2023Dr. Martens plc announced that they will report fiscal year 2023 results on Jun 01, 2023
